Paldara Pharmaceuticals

Protected by Paldara

About Paldara Pharmaceuticals

Paldara is addressing this issue by developing an inexpensive antimicrobial gel coating using bacteriophage to prevent these infections from happening in the first place. Our innovative technology is non-toxic and all components are Generally Recognized as Safe (GRAS) by the FDA. Our bacteriophage cocktail can also combat antibiotic and multi drug resistant bacteria, thus addressing the growing antibiotic resistance crisis in hospital systems.

Tagged with


Problem statement

Catheter Associated Urinary Tract Infections (CAUTIs) are the most common hospital acquired infection in our healthcare systems. These infections are reoccurring, have high rates of antibiotic resistance, and tend to disproportionally effect those with pre-existing conditions. A yearly 1.7 billion dollar economic burden associated with these infections occurs annually along with at least 10,000 deaths reported in hospitals.

Traction information

Paldara opened its R&D lab in January of 2020 after receiving preliminary funding. In December of 2020 we completed our MVP against two of the leading causes of CAUTIs, E. coli (responsible for 65-75% of infections) and K. pneumoniae (responsible for 6-8% of infections). Our Bacteriophage Library consists of over 200 novel bacteriophage with therapeutic lytic capacity and continues to grow with time. We are currently working on closing a seed round to fund the next 18 months of product development for 510K approval.


Profile created.
Added about 2 years ago
Pitch is a Capital Factory product. © Capital Factory 2024. Privacy policy.